HIGHLIGHTS
- who: Carsten-Henning Ohlmann from the (UNIVERSITY) have published the research: LHRH sparing therapy in patients with chemotherapy-nau00efve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial, in the Journal: (JOURNAL) of 16/04/2022
SUMMARY
According to FAS analysis, PSA response rate was 64.7% (22/34 patients) in Arm A compared to 73.5% (25/34 patients) in Arm B. Of note, 4 and 2 patients from Arm A and Arm B were not evaluable for PSA-response according to PCWG2. The most often . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.